Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 24, 2020
Recipharm has reserved capacity to support the anticipated demand for the vaccine (mRNA-1273) and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Kineret
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Hellenic Institute for the Study of Sepsis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 infection.